

## Convenient Synthesis of the Main Dehydrohexapeptide Skeleton Constituting a Macrocyclic Antibiotic, Berninamycin A

Hirohumi Saito, Takahiro Yamada, Kazuo Okumura, Yasuchika Yonezawa, and Chung-gi Shin\*  
Laboratory of Organic Chemistry, Faculty of Engineering, Kanagawa University, Kanagawa-ku, Yokohama 221-8686

(Received February 18, 2002; CL-020154)

The first convenient synthesis of the main dehydrohexapeptide segment of a macrocyclic antibiotic, berninamycin A, containing a 3-hydroxy-L-valine residue and having three vinyl groups and a 1-propenyl group, was accomplished.

The antibiotic berninamycin A (**1**),<sup>1,2</sup> isolated from the culture of *Streptomyces bernensis*, is a unique macrocyclic peptide constructed of polyoxazolythiazole dehydropeptide, as shown in Figure 1. The peptide **1** features a main dehydrohexapeptide skeleton **2** consisted of two substructures, - $\Delta$ Ala-L-HyVal-2-(1-amino-1-ethenyl)-5-methyloxazole-4-carbonyl- $\Delta$ Ala- (**3**, Fragment C) ( $\Delta$ Ala = dehydroalanine, HyVal = 3-hydroxy-L-valine) and -L-Thr-[(Z)-1-amino-1-propenyl]-5-methyloxazole-4-carbonyl- (**4**, Fragment B).<sup>3</sup>




Figure 1. Berninamycin A (**1**).

Recently, we have reported briefly novel syntheses of the central pyridine skeleton (Fragment A),<sup>4,5</sup> L- and D-HyVal,<sup>6</sup> and the main dehydrohexapeptide of berninamycin B,<sup>7</sup> the first of which is the common structure of similar antibiotics, A10255G and J.<sup>8</sup> The attractive structure as well as the bioactivity of **1** prompted us to study the total synthesis and the structure-bioactivity relationship.


Herein, we wish to report a convenient synthesis of the protected **2** [(P)-**2**] by fragment condensation of the precursors of **3** with **4** and then by simultaneous selective  $\beta$ -elimination of the three primary alcohols of the obtained hexapeptide **18**.

Similarly to the case of berninamycin B,<sup>7</sup> attempts to couple dehydrotetrapeptide containing a HyVal residue at the C-terminus with an amine (N-) component dipeptide and, alternatively, a carboxyl (C-) component dehydrotripeptide with tripeptide containing HyVal at the N-terminus were both found to be entirely unsuccessful. Therefore, the N-component tetrapeptide containing the HyVal residue at the second position from the N-terminus in sequence was synthesized and then subjected to the


coupling with the protected **4**. First, the starting *N*, *O*-isopropylidene (Isop)-*N*-Cbz-5-methyloxazole-4-carboxylate **7** (Cbz = benzyloxycarbonyl) was synthesized by oxazolation of the protected Ser- $\Delta$ Abu( $\beta$ -Br)-OMe **6**,<sup>9</sup> derived from *N*, *O*-Isop-*N*-Cbz-L-Ser- $\Delta$ Abu-OMe **5** (Abu = 2-amino-2-butenic acid) and *N*-bromosuccinimide (NBS), with Cs<sub>2</sub>CO<sub>3</sub>.<sup>10</sup> Subsequently, *N*, *O*-deprotection of the Isop group of **7** with trifluoroacetic acid (TFA) and then protection of the hydroxy group with *tert*-butyldiphenylsilyl chloride (TPS-Cl) in the presence of imidazole gave methyl 2-[1-(Cbz)amino-2-(*O*-TPS)]ethyl-5-methyloxazole-4-carboxylate (**8**).<sup>11</sup> *N*-Deprotection of the Cbz group of **8** with 10% Pd/C, followed by coupling with *tert*-butoxycarbonyl (Boc)-L-HyVal-OH by using BOP<sup>12</sup> and (*i*-Pr)<sub>2</sub>NEt gave the corresponding dipeptide **9**. The Boc group of **9** was also deprotected with TFA and then further coupled with *N*, *O*-Isop-*N*-Cbz-Ser-OH by the mixed anhydride method using pivaloyl chloride (Piv-Cl) and Et<sub>3</sub>N to give the protected Ser-L-HyVal-5-methyloxazole derivative **10**. Next, ester hydrolysis of **10** with 1 M LiOH, followed by stepwise elongation with H-L-Ser(TPS)-OMe by the BOP method gave the corresponding tetrapeptide **11**, the Isop group of which was deprotected by using TFA and then the formed primary alcohol was in situ protected with *tert*-butyldimethylsilyl chloride (TBS-Cl) to give *O*-TBS-tetrapeptide **12**. Lastly, after deprotecting the Cbz group of **12** with 10% Pd/C, fragment condensation with **4** by the BOP method proceeded smoothly to give the protected dehydrohexapeptide **13**<sup>13</sup> as the precursor of **2** in 67% yield in two steps from **11**, as shown in Scheme 1. As a result, it was suggested that the final intramolecular cyclization position in the total synthesis of **1** could be definitely specified. This fact is very important and different from the case of berninamycin B.

Furthermore, to examine whether the selective  $\beta$ -elimination of only the primary alcohol of **13** occurs or not, the substrate Boc-HyVal-Ser(TPS)-OMe was independently prepared by coupling of Boc-HyVal-OH with H-Ser(TPS)-OMe. After deprotecting the TPS group with 1 M TBAF (tetrabutylammonium fluoride),  $\beta$ -elimination of only the primary alcohol of the formed **14** was attempted by combinations of various concentrations of methanesulfonyl chloride (Ms-Cl) and Et<sub>3</sub>N. As a result, in the case using Ms-Cl (1.2 equiv) and Et<sub>3</sub>N (1.5 equiv) at -20 °C, only the primary alcohol was selectively protected with Ms group to give the corresponding mesyloxy derivative **15**, accompanied with a small amount of dehydrovalyldipeptide **16**. Subsequently, the *O*-Ms group of **15** was  $\beta$ -eliminated with DBU to give the expected dipeptide **17**,<sup>14</sup> as shown in Scheme 2.


Finally, similarly to the case of **17**, deprotection of three *O*-protecting groups of **13** with 1 M TBAF, followed by  $\beta$ -elimination of the formed dehydrohexapeptide **18** with Ms-Cl and Et<sub>3</sub>N and then DBU in one-pot gave the expected (P)-**2**<sup>15</sup> in 75% yield in two steps, as shown in Scheme 3.



**Scheme 1.** Reagent and conditions: i) a) NBS/THF, b)  $\text{Et}_3\text{N}$ /THF, ii)  $\text{Cs}_2\text{CO}_3$ /dioxane, iii) a) TFA/ $\text{CHCl}_3$ , b) TPSCl, imidazole/DMF, iv) a) 10%Pd-C,  $\text{H}_2$ /MeOH, b) BOP, (*i*-Pr) $_2$ NEt, Boc-HyVal-OH/DMF, v) a) TFA/ $\text{CHCl}_3$ , b) PivCl,  $\text{Et}_3\text{N}$ , MS4A, Cbz-Isop-Ser-OH/DMF, vi) a) 1 M LiOH/MeOH, b) BOP, (*i*-Pr) $_2$ NEt, H-Ser(OTPS)-OMe/DMF, vii) a) TFA/ $\text{CHCl}_3$ , b) TBSCl, imidazole/DMF, viii) a) 10%Pd-C,  $\text{H}_2$ /MeOH, b) BOP, (*i*-Pr) $_2$ NEt, Fragment B/DMF.



**Scheme 2.** Reagent and conditions: i) a) BOP, (*i*-Pr) $_2$ NEt, H-Ser(OTPS)-OMe/DMF, b) 1 M TBAF/THF, ii) MsCl,  $\text{Et}_3\text{N}$ / $\text{CHCl}_3$ , iii) DBU/ $\text{CHCl}_3$ .



**Scheme 3.** Reagent and conditions: i) 1 M TBAF/THF, ii) a) MsCl,  $\text{Et}_3\text{N}$ / $\text{CHCl}_3$ , b) DBU/ $\text{CHCl}_3$ .

The structures of all new products thus obtained were confirmed by the  $^1\text{H}$  NMR spectral data and the satisfactory results of the elemental analyses. In particular, from the  $^1\text{H}$  NMR spectrum of **2**, the appearances of the chemical shifts of six protons of the three vinyl group at  $\delta = 5.42, 5.67, 5.87, 6.24, 6.54$ , and  $6.64$  and that of the olefinic proton of the propenyl group at  $\delta = 6.45\text{--}6.60$  supports the formation of Fragment B-C derivative [(P)-2] of the natural **1**.

In conclusion, it is noteworthy that a convenient synthesis of the main dehydrohexapeptide was achieved by the selective  $\beta$ -elimination of many primary alcohols and the final cyclization position in the total synthesis of **1** could be definitely specified.

This work was partly supported by "High-Tech Research Project" from the Ministry of Education, Culture, Sports, Science and Technology.

## References and Notes

- J. M. Liesch and K. L. Rinehart, *J. Am. Chem. Soc.*, **99**, 1645 (1977).
- H. Abe, K. Kushida, Y. Shiobara, and M. Kodama, *Tetrahedron Lett.*, **29**, 1401 (1988).
- C. Shin, Y. Nakamura, and K. Okumura, *Chem. Lett.*, **1993**, 1405.
- K. Umemura, S. Ikeda, J. Yoshimura, K. Okumura, H. Saito, and C. Shin, *Chem. Lett.*, **1997**, 1203.
- C. Shin, K. Okumura, A. Ito, and Y. Nakamura, *Chem. Lett.*, **1994**, 1301.
- Y. Yonezawa, K. Shimizu, K. Yoon, and C. Shin, *Synthesis*, **2000**, 634.
- T. Yamada, K. Okumura, Y. Yonezawa, and C. Shin, *Chem. Lett.*, **2001**, 102.
- a) L. D. Boeck, D. M. Berry, and R. W. Wetzel, *J. Antibiot.*, **45**, 1222 (1992). b) M. Debono, R. Molly, J. L. Occolowitz, J. W. Paschal, A. H. Hunt, K. M. Michel, and J. M. Martin, *J. Org. Chem.*, **45**, 1809 (1992).
- C. Shin, K. Nanjo, and J. Yoshimura, *Tetrahedron Lett.*, **1974**, 521.
- J. Das, J. A. Reid, D. R. Kronenthal, J. Singh, P. Pansegrau, and R. H. Mueller, *Tetrahedron Lett.*, **33**, 7835 (1992).
- P. Wipf and C. P. Miller, *J. Org. Chem.*, **58**, 3604 (1993).
- BOP: Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate.
- 13**: Colorless amorphous material.  $[\alpha]_D^{24} +6.9^\circ$  (c 0.67, MeOH).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta = 0.00$  (s, 6H, TBS's  $\text{CH}_3 \times 2$ ), 0.80, 0.88, 0.93 (each s, 27H, TPS's  $\text{Bu}' \times 2$ , TBS's *t*-Bu), 1.11, 1.22 (each s, HyVal's  $\text{CH}_3 \times 2$ ), 1.41 (d, 3H, Thr's  $\text{CH}_3$ ,  $J = 6.0$  Hz), 1.50–1.60 (m, 9H, Isop's  $\text{CH}_3 \times 2$ , propenyl's  $\text{CH}_3$ ), 2.45, 2.50 (each s, 6H, oxazole's  $\text{CH}_3 \times 2$ ), 3.66 (s, 3H, OMe), 3.84–4.06 (m, 7H, Ser's  $\alpha\text{-H} \times 3$ , Ser's  $\beta\text{-H} \times 3$ , Thr's  $\alpha\text{-H}$ ), 4.20–4.25 (m, 1H, Thr's  $\beta\text{-H}$ ), 4.37 (d, 1H, HyVal  $\alpha\text{-H}$ ,  $J = 8.5$  Hz), 4.51 (q, 1H, Ser's  $\alpha\text{-H}$ ,  $J = 4.0$  Hz), 4.75 (q, 1H, Ser's  $\alpha\text{-H}$ ,  $J = 8.5$  Hz), 5.04 (s, 2H, Cbz's  $\text{CH}_2$ ), 5.09 (q, 1H, Ser's  $\alpha\text{-H}$ ,  $J = 8.5$  Hz), 6.42 (br s, 1H, propenyl's H), 7.11–7.52 (m, 20H, TPS's Ph  $\times 2$ , Cbz's Ph, NH  $\times 5$ ). Found: C, 63.36; H, 6.96; N, 7.49%. Calcd for  $\text{C}_{80}\text{H}_{106}\text{N}_8\text{O}_{16}\text{Si}_3$ : C, 63.21; H, 7.03; N, 7.37%.
- 17**: Colorless crystals. Mp  $71\text{--}73^\circ\text{C}$ .  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta = 1.22, 1.35$  (each s, 6H, HyVal's  $\text{CH}_3 \times 2$ ), 1.44 (s, 9H, Boc's  $\text{Bu}'$ ), 3.85 (s, 3H, OMe), 4.17 (m, 1H, HyVal's CH), 5.60 (br d, 1H, NH), 5.95, 6.60 (each s, 2H, vinyl's H  $\times 2$ ), 8.79 (br s, 1H, NH).
- (P)-2**: Colorless syrup.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta = 1.21, 1.37$  (each s, 6H, HyVal's  $\text{CH}_3 \times 2$ ), 1.48 (d, 3H, Thr's  $\text{CH}_3$ ,  $J = 6.0$  Hz), 1.51–1.79 (m, 6H, Isop's  $\text{CH}_3 \times 2$ ), 1.67 (s, 3H, propenyl's  $\text{CH}_3$ ), 2.63, 2.94 (each s, 3H, oxazole's  $\text{CH}_3 \times 2$ ), 3.83 (s, 3H, OCH $_3$ ), 3.96 (d, 1H, Thr's  $\alpha\text{-H}$ ,  $J = 8.0$  Hz), 4.27–4.33 (m, 1H, Thr's  $\beta\text{-H}$ ), 4.63 (br d, 1H, HyVal's  $\alpha\text{-H}$ ,  $J = 7.5$  Hz), 5.09–5.12 (m, 2H, Cbz's  $\text{CH}_2$ ), 5.42, 5.67, 5.87, 6.24, 6.54, 6.64 (each s, 6H, vinyl's H  $\times 6$ ), 6.45–6.60 (m, 1H, propenyl's H), 7.08 (d, 1H, NH,  $J = 8.5$  Hz), 7.16–7.27 (m, 6H, Cbz's Ph, NH), 9.25 (br s, 1H, NH), 9.31, 9.62 (each s, 2H, NH  $\times 2$ ). Found: C, 57.89; H, 5.76; N, 13.05%. Calcd for  $\text{C}_{42}\text{H}_{50}\text{N}_8\text{O}_{13}$ : C, 57.66; H, 5.76; N, 12.81%.